GALDAR® (Letrozole) is used for different therapeutic applications including: a) adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer; b) Extended adjuvant treatment of hormonedependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years; c) First line treatment in postmenopausal women with hormone dependent advanced breast cancer; d) Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with antiestrogens; e) Neoadjuvant treatment of postmenopausal women with hormone receptor positive, HER2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated. Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer. Letrozole is a nonsteroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the harem of the aromatase cytochrome P450, resulting in a reduction of estrogen biosynthesis in all tissues where present. GALDAR® is presented in tablets of 2.5mg in packs of 30 tablets.